Status:
COMPLETED
Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
Lead Sponsor:
UCSF Benioff Children's Hospital Oakland
Conditions:
Sickle Cell Disease
Vaso-Occlusive Crisis
Eligibility:
All Genders
10-25 years
Phase:
PHASE2
Brief Summary
Acute vaso-occlusive episodes (VOEs) in sickle cell disease (SCD) are primarily managed with opioids. Tolerance and hyperalgesia to opioids develops due to N-methyl-D-aspartate (NMDA)-receptor mediate...
Detailed Description
In this cohort study, all consenting pediatric sickle-cell patients between 10 and 25 years old who were cared for at UCSF Benioff Children's Hospital Oakland (UCSFBCHO) presenting to the emergency de...
Eligibility Criteria
Inclusion
- All English-speaking, sickle cell patients who receive their care at UCSFBCHO in the Department of Hematology who are 8-to-25-years-old presenting to the emergency department for VOC were asked to enroll.
Exclusion
- Prior adverse reaction to ketamine
- Patients were asked during the consent process if they have ever received ketamine, and if so, if they had any serious adverse reaction, such as difficulty breathing, dysphoria, hallucinations, or allergic reaction. If they have, ketamine was not given to these patients.
- Patients who have received ketamine and experienced nausea or vomiting will be asked if they wish to receive the medication. If they do not, they did not receive ketamine.
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2018
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03296345
Start Date
June 1 2016
End Date
April 1 2018
Last Update
April 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Benioff Children's Hospital and Research Center Oakland
Oakland, California, United States, 94609